{
    "Rank": 563,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01702792",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "W12209"
                },
                "Organization": {
                    "OrgFullName": "Dartmouth-Hitchcock Medical Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Derivation of Tumor Specific Hybridomas",
                "OfficialTitle": "Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas"
            },
            "StatusModule": {
                "StatusVerifiedDate": "April 2018",
                "OverallStatus": "Terminated",
                "WhyStopped": "Investigator is leaving Dartmouth",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "January 2014"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "May 6, 2015",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "May 6, 2015",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "October 3, 2012",
                "StudyFirstSubmitQCDate": "October 5, 2012",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "October 8, 2012",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "April 2, 2018",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "April 4, 2018",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Dartmouth-Hitchcock Medical Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "University of Vermont",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "This is a non-randomized, open-label study in patients with newly diagnosed glioblastoma to determine the ability to generate human hybridomas from lymph nodes draining an autologous tumor vaccine injection and demonstrate that the hybridomas secrete glioblastoma-specific antibodies.",
                "DetailedDescription": "The intradermal vaccine will be injected 20cm in the anterior thigh. Vaccination will be done twice and separated by one week. The first vaccination will be performed approximately 2 weeks after surgery.\n\nApproximately one week after the second vaccination one or two vaccine-draining lymph node(s) will be removed. The lymph node(s) will be identified using SN technology. One or two lymph node(s) will be removed.\n\nLymph nodes will be processed for recovery of B cells and formation of hybridomas."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Glioblastoma"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Immunotherapy, cancer vaccine, glioblastoma, hybridoma"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 1"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "1",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Tumor Vaccine",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "1 x 107 TCE tumor lysate in 0.5 ml Lactated Ringers Solution (approximately 1 mg of tumor lysate protein) and equivalent volume of adjuvant will be injected 2 weeks and 3 weeks (2 vaccinations) after surgery in the intradermal skin of the upper thigh. There will be 2 vaccine administrations and patients will be followed for 2 months after inguinal node removal for any possible vaccine/study-related toxicity.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: Tumor Vaccine"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "Tumor Vaccine",
                            "InterventionDescription": "Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tumor Vaccine"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Autologous Tumor Lysate and Montanide Emulsion"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "number of hybridoma clones that produce anti-glioma antibodies",
                            "PrimaryOutcomeDescription": "The primary technical endpoint demonstrating the feasibility of the pilot study will be based upon the total count of the number of generated hybridoma clones sourced from the dermal vaccine draining lymph nodes that are determined to be producing anti-glioma antibodies.",
                            "PrimaryOutcomeTimeFrame": "6 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Production of Antibodies",
                            "SecondaryOutcomeDescription": "Secondary outcomes will include:\n\nDetermining how many hybridoma clones produce glioblastoma-specific antibodies. The initial secondary endpoint will include the counting of the number of hybridoma clones sourced from the dermal vaccine draining lymph nodes that generate specific glioma antibodies.",
                            "SecondaryOutcomeTimeFrame": "6 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Toxicity of Vaccine",
                            "SecondaryOutcomeDescription": "\u2022 Determining toxicity of vaccine",
                            "SecondaryOutcomeTimeFrame": "6 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Clone Production Rate",
                            "SecondaryOutcomeDescription": "Determining whether B cells sourced from the vaccine nodes produce more anti-tumor antibody hybridomas than the non-vaccine node. The rate of producing these clones will be compared according to the source of the B cells. Thus, B cells recovered from vaccine related nodes will be compared to B cells recovered from the non-vaccine node.",
                            "SecondaryOutcomeTimeFrame": "6 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Lymph Node Biopsy",
                            "SecondaryOutcomeDescription": "Determine the safety and toxicity issues related to the Lymph Node Biopsy",
                            "SecondaryOutcomeTimeFrame": "6 months"
                        }
                    ]
                },
                "OtherOutcomeList": {
                    "OtherOutcome": [
                        {
                            "OtherOutcomeMeasure": "Tumor Binding Characteristics",
                            "OtherOutcomeDescription": "Exploratory objectives will include:\n\nDetermining the rate of tumor binding antibodies from hybridomas derived from circulating B cells.\nDetermining the tumor-binding profile of antibodies present in the blood.",
                            "OtherOutcomeTimeFrame": "6 months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nPatients with confirmed new diagnosis of glioblastoma and who have a yield of at least 8x10(7) tumor cells obtained at the time of surgery\nAge > 18 years\nKPS Score of greater than or equal to 70\nAdequate bone marrow as evidenced by:\n\nAbsolute lymphocyte count > 1,000/uL Platelet count > 50,000/uL\n\nAdequate renal function as evidenced by serum creatinine < 2.0\nPatients must be able to read, understand and provide informed consent to participate in the trial.\nPatients of childbearing potential must agree to use an effective form of contraception during the study and for 90 days following vaccination (an effective form of contraception is an oral contraceptive or a double barrier method)\n\nExclusion Criteria:\n\nA patient may not be enrolled in the trial if any of the following criteria are met:\n\nPatients receiving dexamethasone > 8 mg/day during the week before vaccination.\nPatients who are pregnant or lactating\nPatients with active second malignancy.\nAny other medical conditions, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Camilo Fadul, MD",
                            "OverallOfficialAffiliation": "Dartmouth-Hitchcock Medical Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023",
                "RemovedCountryList": {
                    "RemovedCountry": [
                        "United States"
                    ]
                }
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000005909",
                            "ConditionMeshTerm": "Glioblastoma"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000001254",
                            "ConditionAncestorTerm": "Astrocytoma"
                        },
                        {
                            "ConditionAncestorId": "D000005910",
                            "ConditionAncestorTerm": "Glioma"
                        },
                        {
                            "ConditionAncestorId": "D000018302",
                            "ConditionAncestorTerm": "Neoplasms, Neuroepithelial"
                        },
                        {
                            "ConditionAncestorId": "D000017599",
                            "ConditionAncestorTerm": "Neuroectodermal Tumors"
                        },
                        {
                            "ConditionAncestorId": "D000009373",
                            "ConditionAncestorTerm": "Neoplasms, Germ Cell and Embryonal"
                        },
                        {
                            "ConditionAncestorId": "D000009370",
                            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009375",
                            "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
                        },
                        {
                            "ConditionAncestorId": "D000009380",
                            "ConditionAncestorTerm": "Neoplasms, Nerve Tissue"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M8709",
                            "ConditionBrowseLeafName": "Glioblastoma",
                            "ConditionBrowseLeafAsFound": "Glioblastoma",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4251",
                            "ConditionBrowseLeafName": "Astrocytoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8710",
                            "ConditionBrowseLeafName": "Glioma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M20136",
                            "ConditionBrowseLeafName": "Neoplasms, Neuroepithelial",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M19535",
                            "ConditionBrowseLeafName": "Neuroectodermal Tumors",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M20078",
                            "ConditionBrowseLeafName": "Neuroectodermal Tumors, Primitive",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12008",
                            "ConditionBrowseLeafName": "Neoplasms, Germ Cell and Embryonal",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12005",
                            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12010",
                            "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12015",
                            "ConditionBrowseLeafName": "Neoplasms, Nerve Tissue",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T2518",
                            "ConditionBrowseLeafName": "Glioblastoma",
                            "ConditionBrowseLeafAsFound": "Glioblastoma",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "T2519",
                            "ConditionBrowseLeafName": "Glioma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T4092",
                            "ConditionBrowseLeafName": "Neuroepithelioma",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "C000712049",
                            "InterventionMeshTerm": "Monatide (IMS 3015)"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000276",
                            "InterventionAncestorTerm": "Adjuvants, Immunologic"
                        },
                        {
                            "InterventionAncestorId": "D000007155",
                            "InterventionAncestorTerm": "Immunologic Factors"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M21550",
                            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M17050",
                            "InterventionBrowseLeafName": "Vaccines",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M2854",
                            "InterventionBrowseLeafName": "Immunomodulating Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M254583",
                            "InterventionBrowseLeafName": "Monatide (IMS 3015)",
                            "InterventionBrowseLeafAsFound": "Pragmatic",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M3318",
                            "InterventionBrowseLeafName": "Adjuvants, Immunologic",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9891",
                            "InterventionBrowseLeafName": "Immunologic Factors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "PhSol",
                            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}